Skip to Navigation Skip to Search Skip to Content
Search All Centers

New Tools for Treating and Understanding Mantle Cell Lymphoma

Read Transcript Download/Print Transcript

Published on December 31, 2013

Dr. Stephen Smith, a mantle cell lymphoma (MCL) expert from Seattle Cancer Care Alliance, shares his excitement about recent drug approvals in mantle cell lymphoma (MCL). Dr. Smith explains how treatments are being tailored based on a patient's specific disease and addresses the challenges of integrating new approaches into current treatment regimens. 

Featuring

Partners

Seattle Cancer Care Alliance

Sponsors

Seattle Cancer Care Alliance

You might also like

Transcript | New Tools for Treating and Understanding Mantle Cell Lymphoma

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Doctors from around the world are gathered to discuss the latest particularly in blood?related cancers, and, of course, there are SCCA physicians here, specialists, like, joining us, Dr. Stephen Smith.  He's a specialist in lymphoma.  Dr. Smith, thank you for joining us.  

So this altogether has meant a big challenge for the medical community and has resulted in extrapolation of therapies from other subtypes of lymphoma, and that hasn't always panned out as well as we like.  Now, recently there has been an increasing focus on the biology of mantle cell lymphoma and treatments tailored exactly towards that entity, and building on decades of research there have been recent successes including two drug approvals in the last six months.  

The other drug more recently approved is called ibrutinib, and that drug is—was approved on a breakthrough—was given a breakthrough designation by the FDA, which indicates that it fulfills several criteria and offers responses and effectiveness not seen with any other therapies.  So it was hurried through the FDA with safety in mind but in light of how well it works.  And so that has given great cause for excitement in treating mantle cell lymphoma. 

We also have clinical trials which are coming online of new iterations of therapies, new combinations, and so we recommend that patients become educated in available clinical trials and seek a proactive approach in identifying those.  

Thank you for joining us.  I'm Andrew Schorr.  Remember, knowledge can be the best medicine of all. 

Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.